Table 3.
Heart rate variability and urine catecholamine: patients with and without CPAP treatment
|
Heart rate variability |
Overlap syndrome n = 18# |
|
COPD |
|
||
|---|---|---|---|---|---|---|
|
n = 20@ | ||||||
| Baseline | With CPAP | p | Baseline | With CPAP | p | |
| LF (nu) |
46.6 ± 16.1 |
31.3 ± 16.7 |
0.001 |
31.8 ± 10.8* |
28.7 ± 20.4 |
0.401 |
| HF (nu) |
32.2 ± 12.0 |
43.1 ± 19.1 |
0.029 |
41.9 ± 12.1* |
43.6 ± 19.3 |
0.287 |
| LF/HF |
1.8 ± 1.2 |
0.9 ± 0.7 |
0.003 |
0.9 ± 0.6* |
1.2 ± 1.9 |
0.514 |
|
Urine catecholamines |
Overlap syndrome n = 12$ |
|
COPD |
|
||
|
n = 12$ | ||||||
| |
Baseline |
With CPAP |
|
Baseline |
With CPAP |
|
| Norepinephrine, ug |
17.0 ± 8.4 |
10.4 ± 6.4 |
0.003 |
11.1 ± 5.3* |
11.9 ± 7.5 |
0.485 |
| Epinephrine, ug | 2.4 ± 0.9 | 1.4 ± 0.7 | 0.025 | 1.5 ± 0.6* | 1.8 ± 0.8 | 0.374 |
*P < 0.05; when compared with baseline overlap syndrome group.
P values represent comparisons between before and after CPAP in each corresponding group.
LF low frequency, HF high frequency nu normalized unit.